Elza Lomaia

7PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 24, 2026
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

|Feb 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Michael Lauseker, Tomasz Sacha, Hana Klamova

|May 07, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus

|Mar 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.

Annamaria Brioli, Elza Lomaia, Christian Fabisch

|Aug 22, 2023
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.

Konstantin Bogdanov, Ekaterina Kudryavtseva, Yulia Fomicheva

|Aug 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.

Jorge Cortes, Jane Apperley, Elza Lomaia

Pageof 2

Frequent Collaborators

5 joint publications

Jane F Apperley

4 joint publications

Michael Mauro

4 joint publications

Susanne Saussele

3 joint publications

Andreas Hochhaus